Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Clinical trial NCT05111444 · UNKNOWN
Trial details
- NCT number
- NCT05111444
- Sponsor
- Fudan University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-31
- Primary completion
- 2023-12-31
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.